Clinical TrialID 7571
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
NCT05445089
COVID-19|COVID-19 Pneumonia|COVID-19 Respiratory Infection|COVID-19 Acute Respiratory Distress Syndrome|COVID-19 Lower Respiratory Infection
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7571
- Evidence Id
- 7571
- Core Evidence Id
- 7571
- Source Clinical Trial Id
- 7567
- Herb2 Clinical Trial Id
- HBCT007567
- Nct Id
- NCT05445089
- Title
- Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
- Status
- Completed
- Phase
- Phase 2|Phase 3
- Study Result
- No
- Study Condition
- COVID-19|COVID-19 Pneumonia|COVID-19 Respiratory Infection|COVID-19 Acute Respiratory Distress Syndrome|COVID-19 Lower Respiratory Infection
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
- Intervention
- DRUG: Carvacrol|OTHER: Control group
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Single
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 600
- Outcome Measure
- Mortality Rate Among COVID-19 Patients, The incidence of mortality in the first 15 days., Day 1 to Day 15|Quantitative Evaluation of Inflammatory Mediator Interleukin 6 (IL-6) by test ELISA as Collected Over Time to Day 15, Interleukin 6 (IL-6) in pg/ml, Day 1 to Day 15|Quantitative Evaluation of Immunoglobulin M (IgM) by test ELISA as Collected Over Time to Day 15, IgM in mg/dl, Day 1 to Day 15|Quantitative Evaluation of Immunoglobulin G (IgG) by test ELISA as Collected Over Time to Day 15, IgG in mg/dl, Day 1 to Day 15|Proportion of Patients with COVID-19 who Require Intensive Care Unit (ICU)-Level Care, Mechanical Ventilatory Support (MV), and/or Extracorporeal Membrane Oxygenation (ECMO) Over Time to Day 15, As a measure of disease acuity and severity., Day 1 to Day 15|Requirement for Extracorporeal Membrane Oxygenation (ECMO) in COVID-19 Patients Over Time to Day 15, A measure of disease morbidity., Day 1 to Day 15
- Sponsor Collaborator
- Instituto Venezolano de Investigaciones Cientificas
- Funded By
- OTHER
- Location
- Hospital Dr. Leopoldo Manrique Terrero - Periférico de Coche., Caracas, Miranda, 1090, Venezuela
- Other Id
- LAB-2020-01|ISRCTN registry
- Start Date
- 2020-08-01
- Primary Completion Date
- 2020-11-01
- Completion Date
- 2020-12-15
- First Posted
- 2022-07-06
- Results First Posted
- Last Update Posted
- 2022-07-08
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05445089
- Title Cn
- Title En
- Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients
- Bilingual Status
- semi_complete